KRYS - Krystal Biotech launches early-stage study for KB301 in aesthetic indications August, 25 2020 11:56 AM Krystal Biotech Inc. Krystal Biotech (KRYS +0.2%) has initiated PEARL 1 (Phase 1) study of KB301 for acne scars and facial wrinkles.More news on: Krystal Biotech, Inc., Healthcare stocks news, Read more ...